Congress tightens 340B drug discount rules—but may shrink access for the poorest patients.

What it does

The SUSTAIN 340B Act tightens oversight and accountability in the 340B drug discount program, which allows certain healthcare entities (hospitals, clinics, safety-net providers) to purchase drugs at steep discounts for uninsured and low-income patients. The bill requires covered entities to register contract pharmacies, maintain detailed records, report how they use savings, and submit to audits by HHS and drug manufacturers. It also restricts which patients qualify for the discount, limits how entities can use referral prescriptions, and imposes penalties for violations—including temporary program exclusion and civil fines.

Why we flagged it

The bill's core mechanism is regulatory tightening: it adds registration, audit, reporting, and eligibility-verification requirements to the 340B program. While framed as 'integrity' and 'transparency,' the operative effect is to constrain how covered entities operate and who qualifies for discounts, shifting power toward HHS and manufacturers.

What the text implies

• Narrowing the 'patient' definition (requiring documented outpatient service within 2 years, auditable medical records) may exclude homeless, episodic-care, or highly mobile populations who are among the program's intended beneficiaries.
• The 20% cap on referral prescriptions and mandatory audits for entities exceeding it may discourage covered entities from referring patients to specialists outside their system, potentially fragmenting care coordination.
• Three-year eligibility delays for newly acquired child sites and strict integration requirements may prevent safety-net providers from expanding capacity or acquiring underperforming facilities to serve more patients.
• Manufacturers gain audit rights and can demand data on referral prescriptions, potentially allowing them to restrict discounts or challenge covered entities' eligibility determinations, shifting leverage away from providers.
• Mandatory reporting of charity care, financial demographics, and savings use creates a public record that may invite political pressure or donor scrutiny, potentially chilling entities' willingness to serve the most vulnerable.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill strengthens transparency and accountability in a program designed to help low-income patients access affordable drugs, which is a public benefit. However, it also narrows eligibility (tightening the definition of 'patient'), restricts covered entities' operational flexibility (especially around referral prescriptions and child sites), and creates compliance burdens that may reduce the program's reach or cause some entities to exit, potentially harming the vulnerable populations the prog

Who stands to gain

• pharmaceutical manufacturers (audit rights, data access, ability to challenge eligibility)
• HHS/government (expanded enforcement and audit authority)

Named in the bill

HHS/Secretary of Health and Human Services, Pharmaceutical manufacturers (BMY, PFE, JNJ, GH, DVA), Covered entities (hospitals, FQHCs, safety-net providers), Contract pharmacies, 340B Office of Pharmacy Affairs, Centers for Medicare & Medicaid Services, GAO/Comptroller General, OIG/Inspector General

Where it stands

5 cosponsors: 3 Democrats, 2 Republicans.

• Aug 5, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Aug 5, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.